15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
September 26, 2022 09:00 ET | Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered during the trial to date. Patients are now being monitored for...
BES_Mark.jpg
RAYTHEON ALERT: Bragar Eagel & Squire, P.C. is Investigating Raytheon Technologies Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
December 17, 2021 21:00 ET | Bragar Eagel & Squire
NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Raytheon Technologies...
15-SORRENTO-Therapeutics-Logo-FINAL.png
FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients
July 06, 2021 14:34 ET | Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OA pain to proceed following FDA clearance.Phase 1b data demonstrated RTX safety for a single intra-articular administration without dose limiting toxicity (DLT) at any doses...
BES_Mark.jpg
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Sequential Brands and Raytheon on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
January 22, 2021 20:00 ET | Bragar Eagel & Squire
NEW YORK, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Sequential Brands...
LOGO.jpg
FINAL DEADLINE TUESDAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds Raytheon Technologies Corporation f/k/a Raytheon Company Investors of Important December 29 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RTX, RTN
December 24, 2020 16:12 ET | The Rosen Law Firm PA
NEW YORK, Dec. 24, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Raytheon Technologies Corporation f/k/a Raytheon Company (NYSE:...
LOGO.jpg
ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Raytheon Technologies Corporation f/k/a Raytheon Company Investors of Important Deadline in Securities Class Action First Filed by the Firm; Encourages Investors with Losses in Excess of $100K to Contact Firm – RTX, RTN
December 15, 2020 16:08 ET | The Rosen Law Firm PA
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Raytheon Technologies Corporation f/k/a Raytheon Company (NYSE:...
LOGO.jpg
ROSEN, A TOP RANKED FIRM, Reminds Raytheon Technologies Corporation f/k/a Raytheon Company Investors of Important December 29 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RTX, RTN
December 04, 2020 16:30 ET | The Rosen Law Firm PA
NEW YORK, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Raytheon Technologies Corporation f/k/a Raytheon Company (NYSE:...
ROSEN, TRUSTED INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Raytheon Technologies Corporation – RTX, RTN
October 29, 2020 20:17 ET | The Rosen Law Firm PA
NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Raytheon...
Figure 1:
Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee Pain
September 28, 2020 09:00 ET | Sorrento Therapeutics, Inc.
Phase 1b safety data at 6 month post-administration and Day 84 efficacy data available for all patients enrolled.No dose limiting toxicities at any of the doses tested (up to 30 ug) at 6 months...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial
February 27, 2020 15:30 ET | Sorrento Therapeutics, Inc.
Fourteen subjects with advanced cancer pain received epidural RTX (04 to 15 ug)Most common treatment-related adverse event was transient post-procedure related painThree subjects at the higher doses...